FDA clears MindMaze GO neurorehabilitation platform, easing access to continued outpatient therapy

___ Mind­Maze Con­sol­i­dates First-ever FDA Approval for Inpa­tient and Out­pa­tient Neu­rore­ha­bil­i­ta­tion Ther­a­py (press release): “Mind­Maze, a leader in brain­tech, has today announced that it has obtained FDA clear­ance to launch its portable neu­rore­ha­bil­i­ta­tion prod­uct, Mind­Mo­tion™ GO, in the Unit­ed States. Togeth­er with Mind­Mo­tion PRO (which received FDA clear­ance in 2017), Mind­Mo­tion GO is the next…

Read More